NBInno

NBInno is a clinical-stage biotechnology company focused on the discovery and development of next-generation small molecule therapeutics, primarily in the field of oncology. The company leverages an integrated drug discovery engine that combines structural biology, computational chemistry, and AI-driven modeling to address high-value targets in the DNA damage response (DDR) and protein degradation pathways. Its lead candidate, NBI-9213, is a highly selective inhibitor of Ubiquitin-specific-processing protease 1 (USP1) currently undergoing Phase 1 clinical evaluation for advanced solid tumors. With operations in Suzhou and Beijing, NBInno is committed to advancing a pipeline of first-in-class and best-in-class medicines through internal innovation and global partnerships.